Teva Pharmaceutical Industries Ltd.'s patent infringement settlement with AstraZeneca PLC allows it to launch a generic version of Byetta (exenatide) in the U.S. two years and three months before expiration of the last patent covering the GLP-1 agonist.
Teva announced in a June 23 release that it had settled litigation relating to seven AstraZeneca patents covering the diabetes...